louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04560218: Sublingual vs Intrauterine MISOPROSTOL Plus Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Placebo RCT
Official title: Sublingual Versus Intrauterine MISOPROSTOL in Addition to Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Randomized Placebo Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: To Compare Efficacy Intrauterine vs Sublingual MISOPROSTOL in Addition to Oxytocin in Reducing Blood Loss of Post-cesarean Section in High Risk Women
Keywords: Postpartum hemorrhage, Cesarean section, Sublingual Misoprostol, Intrauterine Misoprostol
Lead sponsor: Department of Medical Services Ministry of Public Health of Thailand
Sponsor class: OTHER_GOV
First posted: 2020-09-23
Enrollment: 135
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Research Objective:

Primary outcome

-To compare efficacy Intrauterine vs Sublingual MISOPROSTOL in addition to Oxytocin in reducing blood loss of post-cesarean section in high risk women

Secondary outcome

-To study Hemoglobin/Hematocrit change, need of uterotonic agents, need of blood transfusion, adverse drug event of Intrauterine vs Sublingual Misoprostol plus Oxytocin compare to Oxytocin alone

Hypothesis:

-Intrauterine MISOPROSTOL plus Oxytocin is not inferior to Sublingual MISOPROSTOL plus Oxytocin in reducing blood loss of post-cesarean section in high risk women

Detailed description: Research Design: Double-blind Randomized Placebo Controlled Trial

Subject: Singleton pregnancy GA 34 wk or more with high risk for postpartum hemorrhage undergo cesarean section with spinal anesthesia in Rajavithi Hospital

Allocated to 3 groups

* group1: Misoprostol sublingually 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab
* group2: Misoprostol Intrauterine 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo sublingually 2 tab
* group3: Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab + Placebo sublingually 2 tab

Eligibility criteria: Inclusion Criteria:

* ≥35 ปี
* Previous PPH
* Morbid obesity
* Fetal macrosomia
* Polyhydramnios
* Induction/Augmentation of Labour
* Prolonged Labour
* Grand multiparity
* Preeclampsia
* Myoma Uteri

Exclusion Criteria:

* Asthma
* Maternal fever/ Tripple I can't excluded
* coagulopathy
* Placenta previa/ adherens/ abruptio placenta
* Allergy to Prostaglandins/Oxytocin

Primary outcomes:
measure: Blood loss
timeFrame: operation time
Secondary outcomes:
measure: Hemoglobin/Hematocrit change
timeFrame: until 24 hours post-operation
measure: need of uterotonic agents
timeFrame: until 24 hours post-operation
measure: need of blood transfusion
timeFrame: until 24 hours post-operation
measure: adverse drug event
timeFrame: until 24 hours post-operation
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Rajavithi hospital
Study officials:
References:
Clinical trial NCT00275418: Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease
Official title: Double-Blind Randomized Prospective Trial of Treatment With Natural Beta Carotene Vs. Placebo for Patients With Crohn's Disease in Remission
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Crohn's Disease
Keywords: Crohn's disease
remission
beta carotene
Lead sponsor: Bnai Zion Medical Center
Sponsor class: OTHER_GOV
First posted: 2006-01-12
Enrollment: 300
Sex: ALL
Minimum age (years): 17
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Many inflammatory disorders in the body are linked to oxidative tissue damage. Anti-oxidants that are present in many natural food sources may provide protection from such damage.

Beta carotene is an anti-oxidant vitamin present in many fruits and vegetables. The algae Dunaliella is particularly rich in beta carotene.

In this prospective trial we want to investigate whether beta carotene from Dunaliella may prevent exacerbations of Crohn's disease.

Detailed description: Patients with documented Crohn's disease who are at least 2 months in remission (CDAI\<150) will be randomized to receive 60 mg beta carotene/day vs. placebo for 1 year.

The study medication will be taken in addition to regular treatment for Crohn's disease.

The protocol includes 5 visits (months 0, 3, 6, 9, 12). Each visit lasts 30-60 minutes and includes a brief interview, standard questionnaires, physical examination, and blood tests.

Exacerbation of Crohn's disease is defined as CDAI\>150. The study hypothesis is that less patients treated with beta carotene will suffer an exacerbation than patients treated with placebo.

Eligibility criteria: Inclusion Criteria:

* patients with documented Crohn's disease in remission (CDAI\<150) for at least two months, age 17-75 years

Exclusion Criteria:

* active Crohn's disease (CDAI\>150), partial bowel obstruction, impending surgery, pregnancy, serious other diseases

Primary outcomes:
measure: CDAI score measured 3-monthly during treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Bnai Zion Medical Center
Study officials:
affiliation: Technion, Haifa, Israel
name: Alexandra Lavy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05453318: Efficacy and Acceptability of Thermal Ablation in the Treatment of Cervical Neoplasia
Official title: Efficacy and Acceptability of Thermal Ablation in the Treatment of Cervical Neoplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Neoplasm
Lead sponsor: International Agency for Research on Cancer
Sponsor class: OTHER
Collaborators: name: Referral Centre of Reproductive Health, Fez, Morocco
name: Referral Centre of Reproductive Health, Taza, Morocco
First posted: 2022-07-12
Enrollment: 119
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This is a single arm study where women presenting with cervical lesions eligible to ablation were treated and followed-up for cure and adverse events.
Primary purpose: TREATMENT

Brief summary: Longitudinal study in two referral centers in Morocco to evaluate the effectiveness, the acceptability and safety of thermal ablation in the treatment of cervical neoplasia.

Detailed description: The study population consisted of women with a positive Visual Inspection with Acetic Acid (VIA) screening test referred for ablative treatment. A total of 119 women with lesions eligible to ablative treatment were counselled and treated by thermal ablation. Informed consent was signed by each participant. Just after treatment, the patients were inquired about the level of pain during the procedure, and their level of satisfaction with the treatment. The women were followed-up at 6 weeks for any complication and re-assessed by colposcopy and biopsy at 12 months for any persistent or recurrent lesion and for any adverse event.

Eligibility criteria: Inclusion Criteria:

* Women having been screened positive at VIA at the primary health center and referred to the diagnosis centre of Fez and Taza for ablative treatment by thermal ablation

Exclusion Criteria:

* Lesion occupying the 4 quadrants of the cervix
* Not visible squamous columnar junction (not Type 1 TZ (transformation zone))
* Vaginal or endocervical lesion
* Lesion subjective of cervical cancer

Primary outcomes:
measure: Cure rate based on colposcopy and histology assessment
timeFrame: 1 year
Secondary outcomes:
measure: Acceptability of thermal ablation in terms of adverse events
timeFrame: 1 year
measure: Acceptability of thermal ablation in terms of satisfaction level
timeFrame: Within one hour after procedure
measure: Safety of TA in terms of major adverse events
timeFrame: 1 year
Other outcomes:
Locations:
city: Fez
country: Morocco
facility: Referral Centre of Reproductive Health
Study officials:
affiliation: Diagnosis Centre, TAZA
name: Zakia GHAFFOULI, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Diagnosis Centre, Fez
name: Hanane BELCADI ABBASSI, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06523218: A Clinical Trial to Investigate the Efficacy of a Supplement to Improve and Maintain Cognitive Function and Memory
Official title: A Clinical Trial to Investigate the Efficacy of a Supplement to Improve and Maintain Cognitive Function and Memory
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Cognitive Decline
Cognitive Function
Keywords: Cognitive Health
Healthy Aging
Lead sponsor: Scale Media Inc
Sponsor class: INDUSTRY
Collaborators: name: Citruslabs
First posted: 2024-07-26
Enrollment: 50
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the efficacy of 1MD Nutrition's MindMD supplement in improving and maintaining cognitive function and memory. The randomized controlled trial will include 50 healthy participants aged 50-75 years, lasting for 3 months. Participants will be randomized to receive either the test product or a placebo.


Eligibility criteria: Inclusion Criteria:

* Age 50-75 years
* Regular experience of symptoms related to cognitive decline (e.g., forgetfulness, lack of focus, brain fog)
* Generally healthy without uncontrolled chronic diseases
* Willingness to avoid certain medications and supplements during the study

Exclusion Criteria:

* Any medical condition or treatment impacting cognitive ability Mental health or neurological disorders
* Severe allergies, particularly to soy or other product ingredients
* Taking blood thinning medication
* Recent or planned surgeries
* Major illness in the past three months

Primary outcomes:
measure: Cognitive Function and Memory Improvement
timeFrame: Baseline, Month 2, and Month 3
Secondary outcomes:
measure: Participants' Perceptions of Cognitive Function and Memory using the Cognitive Function Questionnaire
timeFrame: Baseline, Month 1, Month 2, and Month 3
measure: Participants' Quality of Life
timeFrame: Baseline, Month 1, Month 2, and Month 3
measure: Participants' Focus and Attentiveness
timeFrame: Baseline, Month 1, Month 2, and Month 3
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Citruslabs
state: California
Study officials:
References:
Clinical trial NCT03110718: Role of Armeo-Power and Muscle Vibration in Upper Limb Rehabilitation
Official title: Can Upper Limb Robotic Rehabilitation Plus Muscle Vibration Improve Motor Function? A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Keywords: robotic rehabilitation
muscle vibration
combined approach
Lead sponsor: IRCCS Centro Neurolesi Bonino Pulejo
Sponsor class: OTHER
First posted: 2017-04-12
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Muscle vibration (MV) has been suggested as a useful non-pharmacological approach to control spasticity. Armeo Power® (AP) is a robotic exoskeleton for rehabilitation allowing early rehabilitation treatment. The objective of our study was to determine whether AP training coupled with MV applied on antagonist muscles of the spastic upper limb (UL) can reduce the spasticity of agonist muscles. We enrolled 20 chronic post-stroke patients, who underwent 40 daily sessions of AP training. Ten subjects (group-A) received muscle MV (on triceps brachii, deltoid, and supraspinatus), whereas the other 10 (group-B) underwent a sham vibration.


Eligibility criteria: Inclusion Criteria:

* a first ever supra-tentorial unilateral (left hemisphere) ischemic stroke experienced more than three months before the enrollment;
* a deficit of shoulder abductor, arm flexor, and elbow extensor muscles ranging from 2 to 4 on the Medical Research Council scale (MRC);
* a spasticity of biceps brachii (BB), pectoralis major (PM), and latissimus dorsi (LD) (namely, spastic agonist muscles) ranging from 1+ to 3 on the Modified Ashworth Scale (MAS);
* age between 50 and 80 years; and (v) Caucasian ethnicity.

Exclusion Criteria:

* history of concomitant neurodegenerative diseases or brain surgery;
* severe cognitive (Mini-Mental State Examination score \<23 points) or language impairment (Boston Disability Aphasia Quotient \<4/5);
* severe neglect (Catherine Bergego Scale \>15/30);
* systemic, bone, or joint disorders, tumors, changes in either central or peripheral sensitivity as well as visual impairments able to interfere with the aims and methods of the research;.(v) concomitant use of drugs for spasticity;
* botulin toxin treatment in the last eight months;.(vii) TMS contraindications;
* history of psychosis;
* limited passive range of motion (shoulder abduction \<60°, elbow extension \<30°, specified by a goniometric assessment).

Primary outcomes:
measure: Assessment of spasticity-MAS
timeFrame: Six months
Secondary outcomes:
measure: Fugl-Meyer Assessment of UL motor recovery after stroke -FMA
timeFrame: Six months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04787718: Almond for Physical Performance
Official title: Roles of Almonds in Physical Performance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Muscle Soreness
Energy
Lead sponsor: San Diego State University
Sponsor class: OTHER
First posted: 2021-03-09
Enrollment: 30
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Investigators specific aims are to compare the effects of consuming daily snacks of raw, shelled, unsalted almonds (2.0 ounces) versus an isocaloric amount of another commonly consumed snack food (pretzels) on energy (vigor) perception and physical activity, exercise performance (VO2max and measures of strength), strength and power performance as well as muscle soreness recovery after strenuous eccentrically-biased exercise.

Detailed description: To accomplish these aims, investigators will examine whether regular consumption of almonds versus a common snack food over a period of 8 weeks impacts longer term metabolic, physiological and behavioral responses related to energy sensations and exercise capacity/performance.

Eligibility criteria: Inclusion Criteria:

* 30-50 years old
* BMI of 23-30

Exclusion Criteria:

* smoking,
* medications known to impact inflammation,
* musculoskeletal limitations and
* use of supplements within 1 month of participation that are known to impact antioxidant
* use of supplements within 1 month of participation that are known to impact inflammatory status

Primary outcomes:
measure: Changes from baseline in energy (vigor) perception
timeFrame: At baseline , at 8 weeks
measure: Changes from baseline in exercise performance
timeFrame: At baseline , at 8 weeks
Secondary outcomes:
measure: Changes from baseline in strength and power performance
timeFrame: At baseline, at 8 weeks
measure: Changes from baseline in muscle soreness
timeFrame: At baseline, at 8 weeks
Other outcomes:
Locations:
city: San Diego
country: United States
facility: San Diego State University
state: California
Study officials:
References:
Clinical trial NCT00488618: Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
Official title: A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in Patients With Acute Mania Associated With Bipolar I Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Bipolar Disorder
Keywords: Mania
Bipolar I Disorder
Acute Mania Associated with Bipolar I Disorder
Lead sponsor: Forest Laboratories
Sponsor class: INDUSTRY
Collaborators: name: Gedeon Richter Ltd.
First posted: 2007-06-20
Enrollment: 238
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania. This study will be 5 weeks in duration; 3 weeks double-blind treatment and 2-weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of two treatment groups: RGH-188 or placebo


Eligibility criteria: Inclusion Criteria:

* Male or female inpatients 18 to 65 years of age
* Meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV) criteria for bipolar I disorder, acute manic or mixed episode
* Having a total Young Mania Rating Scale (YMRS) score \>= 20 and a score of at least 4 on two of the following YMRS items:

  * Irritability,
  * Speech,
  * Content, and
  * Disruptive/Aggressive Behavior

Exclusion Criteria:

* Patients who exhibit abnormalities on physical examination, have abnormal vital-signs, electrocardiogram (ECG), or clinical laboratory values \[such as thyroid-stimulating hormone (TSH)\].
* Patients with Montgomery-Åsberg Depression Rating Scale (MADRS) total score \>= 18 at Visit 2.
* Patients experiencing first manic episode.
* Patients that have received electroconvulsive therapy (ECT) or a depot neuroleptic in the 3 months prior to Visit 1.

Primary outcomes:
measure: Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3
timeFrame: Baseline, Week 3
Secondary outcomes:
measure: Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3
timeFrame: Baseline, 3 Weeks
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: For information regarding investigative sites, contact Forest Professional Affairs
state: Missouri
Study officials:
References:
citation: McIntyre RS, Masand PS, Earley W, Patel M. Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord. 2019 Oct 1;257:600-606. doi: 10.1016/j.jad.2019.07.020. Epub 2019 Jul 5.
citation: Earley W, Durgam S, Lu K, Ruth A, Nemeth G, Laszlovszky I, Yatham LN. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. 2018 Jan 15;226:239-244. doi: 10.1016/j.jad.2017.09.040. Epub 2017 Sep 25.
Clinical trial NCT06414018: Effect of Equivalent Dose of Alfentanil and Sufentanil in Bronchoscopic Treatment
Official title: Effect of Equivalent Dose of Alfentanil and Sufentanil Combined With Remimazolam in Complex Bronchoscopic Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Effect of Drug
Keywords: Afentanil
sufentanil
bronchoscopy
Recovery time
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
Collaborators: name: Xinxiang Central Hospital
First posted: 2024-05-14
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The equivalent dose of sufentanil and afentanil combined with laryngeal mask was used for complex bronchoscopy to observe the intraoperative effect and the influence on the recovery of patients

Detailed description: Afentanil is a powerful, fast-acting narcotic analgesic, which can effectively inhibit intubation reflex. Compared with sufentanil, it has a short half-life and is safer, and can be used as the first choice for short surgical analgesics. In this study, by comparing the use of equivalent dose sufentanil and afentanil combined with laryngeal mask for complex bronchoscopy, the intraoperative analgesic effect and the influence on the recovery of patients were observed, and a better anesthesia scheme was provided for tracheoscopy.

Eligibility criteria: Inclusion Criteria:

* Age 18-80,
* ASA I-III level;
* BMI 18.5\~23.9;

Exclusion Criteria:

* Patients with full stomach and high risk of reflux aspiration;
* Allergic to benzodiazepines, opioids, rocuronium bromide;
* Those who have taken sedative, analgesic or antidepressant drugs within 24 hours;
* Pregnant and lactating women;
* severe liver and kidney dysfunction;
* Patients with severe anemia and hypoproteinemia;
* Previous drug use history;
* Recently participated in other clinical studies;
* Patients who cannot cooperate with communication.

Primary outcomes:
measure: time of Recovery
timeFrame: 1day
Secondary outcomes:
measure: Time records
timeFrame: 1 day
measure: dose of drugs
timeFrame: 1 day
measure: rate of respiratory suppression incidence
timeFrame: 1 day
measure: rate of Incidence of Treatment-Emergent Adverse Events
timeFrame: 1day
Other outcomes:
measure: rate of Postoperative adverse reaction
timeFrame: 1 day
Locations:
city: Hubei
country: China
facility: Aijun Xu
state: Wuhan
Study officials:
affiliation: Tongji Hospital
name: aijun xu, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02356718: Cognitive Training in Inpatient Treatment for Substance Use Disorders
Official title: Cognitive Training in Inpatient Treatment for Substance Use Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Substance Use Disorders
Lead sponsor: Centre for Addiction and Mental Health
Sponsor class: OTHER
First posted: 2015-02-05
Enrollment: 111
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study examines whether computer tasks can improve memory and other cognitive functions among patients receiving inpatient treatment for substance use disorders.

Detailed description: Participants will complete cognitive training sessions on a regular basis during inpatient treatment. Alternate versions of the computer tasks will be compared in a randomized design. Primary and secondary outcomes will consist of changes in cognitive performance before and after the training period.

Eligibility criteria: Inclusion Criteria:

* Participants must be patients registered for inpatient treatment at the Centre for Addiction and Mental Health
* Age 18-60
* Fluency in English
* Able to attend scheduled training sessions
* Comfortable using a computer and mouse

Exclusion Criteria:

* Severe cognitive impairment
* Current or past psychosis or diagnosis of schizophrenia
* Photosensitive epilepsy or history of seizures triggered by light
* Legal mandate to attend treatment

Primary outcomes:
measure: Auditory memory capacity - WAIS Digit Span score
timeFrame: Baseline, 3 weeks
Secondary outcomes:
measure: Auditory memory capacity - WAIS Letter-number sequencing score
timeFrame: Baseline to 3 weeks
measure: Visual memory capacity - WMS Spatial span score
timeFrame: Baseline to 3 weeks
measure: Visual memory capacity - WMS Symbol span score
timeFrame: Baseline to 3 weeks
measure: Training progress score - Cognitive progress indicator score
timeFrame: Baseline to 4 weeks
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Centre for Addiction and Mental Health
state: Ontario
Study officials:
affiliation: Centre for Addiction and Mental Health
name: Christian Hendershot, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hendershot CS, Wardell JD, Vandervoort J, McPhee MD, Keough MT, Quilty LC. Randomized trial of working memory training as an adjunct to inpatient substance use disorder treatment. Psychol Addict Behav. 2018 Dec;32(8):861-872. doi: 10.1037/adb0000415. Epub 2018 Nov 26.